Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ventana to create a companion diagnostic for Pfizer’s Xalkori

Executive Summary

Marking its third deal in less than a week, Roche Diagnostics Corp.’s tissue-based cancer diagnostics unit Ventana Medical Systems Inc. has agreed to develop an automated and standardized immunohistochemistry companion test for Pfizer Inc.’s Xalkori (crizotinib), recently approved and launched in the US for non-small cell lung cancer with mutations in the anaplastic lymphoma tyrosine kinase (ALK) gene. Ventana is also in-licensing an antibody from Cell Signaling Technology Inc. to use in the assay.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register